• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

高危多发性骨髓瘤患者 upfront 串联自体非清髓异基因造血干细胞移植：一项长期单中心经验。

Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.

机构信息

Department of Clinical Haematology, Alfred Health, Melbourne, Victoria, Australia.

Australian Centre for Blood Diseases, Monash University, Melbourne, Victoria, Australia.

出版信息

Intern Med J. 2022 Jul;52(7):1263-1267. doi: 10.1111/imj.15842. Epub 2022 Jul 9.

DOI:10.1111/imj.15842
PMID:35808923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9543527/
Abstract

The role of upfront non-myeloablative allogeneic stem cell transplantation (NMA alloSCT) in high-risk multiple myeloma (HR-MM) is unclear. We evaluated outcomes of NMA alloSCT following autologous stem cell transplant (ASCT) compared with ASCT alone for newly diagnosed HR-MM. Two-year progression-free survival was improved in the ASCT-NMA alloSCT group (44% vs 16%; P = 0.035), with a trend for improved overall survival (P = 0.118). These results suggest that ASCT-NMA alloSCT can be considered as upfront therapy in HR-MM.

摘要

upfront 非清髓性异基因造血干细胞移植（NMA alloSCT）在高危多发性骨髓瘤（HR-MM）中的作用尚不清楚。我们评估了与单独自体造血干细胞移植（ASCT）相比，ASCT 后接受 NMA alloSCT 治疗新诊断的 HR-MM 的结果。ASCT-NMA alloSCT 组的 2 年无进展生存率提高（44% vs 16%；P=0.035），总生存率也有改善的趋势（P=0.118）。这些结果表明，ASCT-NMA alloSCT 可作为 HR-MM 的一线治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c37/9543527/7035d1d5e9e3/IMJ-52-1263-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c37/9543527/7035d1d5e9e3/IMJ-52-1263-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c37/9543527/7035d1d5e9e3/IMJ-52-1263-g002.jpg

相似文献

1
Upfront tandem autologous non-myeloablative allogeneic stem cell transplant in high-risk multiple myeloma: a long-term single-centre experience.高危多发性骨髓瘤患者 upfront 串联自体非清髓异基因造血干细胞移植：一项长期单中心经验。
Intern Med J. 2022 Jul;52(7):1263-1267. doi: 10.1111/imj.15842. Epub 2022 Jul 9.
2
Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.多发性骨髓瘤清髓性异基因干细胞移植的长期疗效
Biol Blood Marrow Transplant. 2007 Aug;13(8):925-31. doi: 10.1016/j.bbmt.2007.04.006. Epub 2007 May 29.
3
Adverse impact of high donor CD3+ cell dose on outcome following tandem auto-NMA allogeneic transplantation for high-risk myeloma.高供体CD3+细胞剂量对高危骨髓瘤串联自体-非清髓性异基因移植后结局的不良影响。
Bone Marrow Transplant. 2017 Jun;52(6):839-845. doi: 10.1038/bmt.2017.37. Epub 2017 Mar 20.
4
Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.CALGB（Alliance）100001 研究的长期随访结果：自体造血干细胞移植后序贯非清髓性异基因造血干细胞移植治疗多发性骨髓瘤。
Biol Blood Marrow Transplant. 2020 Aug;26(8):1414-1424. doi: 10.1016/j.bbmt.2020.03.028. Epub 2020 Apr 20.
5
Younger donor's age and upfront tandem are two independent prognostic factors for survival in multiple myeloma patients treated by tandem autologous-allogeneic stem cell transplantation: a retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).年轻供者年龄和 upfront tandem 是接受 tandem 自体-异基因干细胞移植治疗的多发性骨髓瘤患者生存的两个独立预后因素：来自法国骨髓和细胞治疗协会（SFGM-TC）的回顾性研究。
Haematologica. 2012 Apr;97(4):482-90. doi: 10.3324/haematol.2011.049742. Epub 2011 Nov 4.
6
The role of tandem stem cell transplantation for multiple myeloma patients.串联干细胞移植在多发性骨髓瘤患者中的作用。
Expert Opin Biol Ther. 2016;16(4):515-34. doi: 10.1517/14712598.2016.1136285. Epub 2016 Feb 6.
7
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis.自体移植治疗新诊断多发性骨髓瘤在新型诱导药物时代：系统评价和荟萃分析。
JAMA Oncol. 2018 Mar 1;4(3):343-350. doi: 10.1001/jamaoncol.2017.4600.
8
Allogeneic stem cell transplantation for multiple myeloma.异基因干细胞移植治疗多发性骨髓瘤。
Hematol Oncol Clin North Am. 2014 Oct;28(5):891-902. doi: 10.1016/j.hoc.2014.06.001. Epub 2014 Jul 25.
9
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.卡非佐米联合环磷酰胺和地塞米松或来那度胺和地塞米松联合自体移植，或卡非佐米联合来那度胺和地塞米松，随后用卡非佐米联合来那度胺或来那度胺维持治疗新诊断的多发性骨髓瘤患者（FORTE）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
10
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.造血干细胞移植治疗多发性骨髓瘤的应用：梅奥多发性骨髓瘤分层与风险适应性治疗（mSMART）共识声明。
Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9.

引用本文的文献

1
Efficacy and survival outcome of allogeneic stem-cell transplantation in multiple myeloma: meta-analysis in the recent 10 years.异基因干细胞移植治疗多发性骨髓瘤的疗效与生存结果：近10年的荟萃分析
Front Oncol. 2024 Jul 31;14:1341631. doi: 10.3389/fonc.2024.1341631. eCollection 2024.

本文引用的文献

1
Predicting ultrahigh risk multiple myeloma by molecular profiling: an analysis of newly diagnosed transplant eligible myeloma XI trial patients.通过分子谱分析预测超高风险多发性骨髓瘤：对新诊断的适合移植的骨髓瘤XI试验患者的分析
Leukemia. 2020 Nov;34(11):3091-3096. doi: 10.1038/s41375-020-0750-z. Epub 2020 Mar 11.
2
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.来那度胺维持治疗在新诊断的多发性骨髓瘤自体干细胞移植后的应用：一项荟萃分析。
J Clin Oncol. 2017 Oct 10;35(29):3279-3289. doi: 10.1200/JCO.2017.72.6679. Epub 2017 Jul 25.
3
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.
新诊断骨髓瘤的预后预测：1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
4
Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group.高危细胞遗传学特征的多发性骨髓瘤的治疗：国际骨髓瘤工作组共识
Blood. 2016 Jun 16;127(24):2955-62. doi: 10.1182/blood-2016-01-631200. Epub 2016 Mar 21.
5
Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation.接受大剂量化疗和自体造血干细胞移植的高危和标危多发性骨髓瘤患者的治疗结果
Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):687-93. doi: 10.1016/j.clml.2015.07.641. Epub 2015 Aug 5.
6
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.多发性骨髓瘤修订国际分期系统：国际骨髓瘤工作组报告
J Clin Oncol. 2015 Sep 10;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267. Epub 2015 Aug 3.
7
Safe and effective use of outpatient non-myeloablative allogeneic stem cell transplantation for myeloma.门诊非清髓性异基因干细胞移植治疗骨髓瘤的安全有效应用。
Blood Cancer J. 2014 May 9;4(5):e213. doi: 10.1038/bcj.2014.33.
8
IMWG consensus on risk stratification in multiple myeloma.IMWG 共识：多发性骨髓瘤的风险分层。
Leukemia. 2014 Feb;28(2):269-77. doi: 10.1038/leu.2013.247. Epub 2013 Aug 26.
9
Tandem autologous vs autologous plus reduced intensity allogeneic transplantation in the upfront management of multiple myeloma: meta-analysis of trials with biological assignment.自体 tandem 移植与自体移植联合减低强度异基因移植在多发性骨髓瘤一线治疗中的比较：基于生物学分组的临床试验荟萃分析。
Bone Marrow Transplant. 2013 Apr;48(4):562-7. doi: 10.1038/bmt.2012.173. Epub 2012 Sep 10.
10
Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care.异基因造血干细胞移植治疗多发性骨髓瘤：可治愈但并非标准治疗。
Curr Opin Oncol. 2012 Nov;24(6):720-6. doi: 10.1097/CCO.0b013e328358f619.